Skip to main content

Table 2 Comparison of neoadjuvant hormonal therapy period treated with laparoscopic radical prostatectomy patients

From: Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy

Variables Group A* Group B**
No. of patients 47 25
Mean age ± SD 67.4 ± 5.6 68.3 ± 4.7
Preoperative serum PSA ± SD, ng/mL 10.0 ± 3.9 9.38 ± 4.4
Biopsy Gleason grade, n(%)
 ≤ 3 + 3 20 (42.6) 10 (40.0)
 3 + 4, 4 + 3 20 (42.6) 5 (20.0)
 ≥ 4 + 4 7 (14.9) 10 (40.0)
D’Amico risk classification, n(%)
 low 11 (23.4) 3 (12.0)
 intermediate 17 (36.2) 7 (28.0)
 high 19 (40.4) 15 (60.0)
Kind of neoadjuvant hormonal therapy
 CAB 32 (68.1) 18 (72.0)
 anti-androgen alone 15 (31.9) 7 (28.0)
Pathological stage, n(%)
 pT2 42 (89.4) 20 (80.0)
 pT3a 3 (6.40) 4 (16.0)
 pT3b 2 (4.30) 1 (4.00)
Median operative time, min 286 (151–454) 270 (152–410)
Median blood loss, ml 600 (90–3928) 552 (95–1600)
Positive surgical margin, n(%) 13 (27.7) 7 (28.0)
Biochemical recurrence, n(%) 13 (27.7) *1 (4.00)
  1. Patient characteristics and outcomes in two NHT patient groups (Group A: NHT on LRP for less than 3 months, Group B: NHT on LRP for more than 3 months) *p < 0.05.
  2. Group A*: laparoscopic radical prostatectomy cases treated with neoadjuvant hormonal therapy for less than 3 months.
  3. Group B**: laparoscopic radical prostatectomy cases treated with neoadjuvant hormonal therapy for more than 3 months.
  4. CAB: combined androgen blockade with anti-androgen and LHRH analogue. *p < 0.05.
  5. CAB: combined androgen blockade with anti-androgen and LHRH analogue.